Article

Repurposing polyamines to prevent arrhythmias in Short QT Syndrome type 3, a potentially lethal disease

2025-09-16

Abstract excerpt

<h4>ABSTRACT</h4> Short QT Syndrome type 3 (SQTS3) is a channelopathy characterized by the abbreviation of the QT interval on electrocardiogram and life-threatening arrhythmias. SQTS3 is caused by gain-of-function mutations in KCNJ2 , which codes the strong inward rectifier potassium channel Kir2.1 responsible for the repolarizing current I K1 . Inward- going rectification of I K1 is due to a voltage-dependent...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 28bf5491-d5bc-5d5f-87e6-607a6004bcaa
DOI: 10.1101/2025.09.10.675300

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Repurposing polyamines to prevent arrhythmias in Short QT Syndrome type 3, a potentially lethal diseaseDOI 10.1101/2025.09.10.675300Read

Repurposing polyamines to prevent life-threatening arrhythmias in Short QT Syndrome type 3.Semantic proximity Read

The Kir2.1E299V mutation increases atrial fibrillation vulnerability while protecting the ventricles against arrhythmias in a mouse model of short QT syndrome type 3.Semantic proximity Read

A novel gain-of-function KCNJ2 mutation associated with short-QT syndrome impairs inward rectification of Kir2.1 currents.Semantic proximity Read

A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene.Semantic proximity Read

<i>KCNJ2</i> mutation in short QT syndrome 3 results in atrial fibrillation and ventricular proarrhythmiaSemantic proximity Read

Patient-Specific and Gene-Corrected Induced Pluripotent Stem Cell-Derived Cardiomyocytes Elucidate Single-Cell Phenotype of Short QT SyndromeSemantic proximity Read

Defining Cardiomyocyte Repolarization Response to Pharmacotherapy in Long-QT Syndrome Type 3.Semantic proximity Read

Preclinical short QT syndrome models: studying the phenotype and drug-screening.Semantic proximity Read

Emerging therapeutic targets in the short QT syndrome.Semantic proximity Read

Congenital short QT syndrome: landmarks of the newest arrhythmogenic cardiac channelopathy.Semantic proximity Read

Long QT syndrome: biophysical and pharmacologic mechanisms in LQT3.Semantic proximity Read

Prime-edited isogenic hiPSC-derived cardiomyocyte model of short QT syndrome type 3 reveals electrophysiological phenotypes and differential drug responses.Semantic proximity Read